PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Negative EBIT growth while AGEN is at 39.26%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-14.64%
Negative operating income growth while AGEN is at 37.60%. Joel Greenblatt would press for urgent turnaround measures.
-15.16%
Negative net income growth while AGEN stands at 26.48%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
2.78%
EPS growth under 50% of AGEN's 28.75%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
2.78%
Diluted EPS growth under 50% of AGEN's 28.75%. Michael Burry would worry about an eroding competitive position or excessive dilution.
19.07%
Share count expansion well above AGEN's 3.28%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
19.07%
Diluted share count expanding well above AGEN's 3.28%. Michael Burry would fear significant dilution to existing owners' stakes.
-16.01%
Dividend reduction while AGEN stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-25.31%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-30.01%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2395.20%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
87.33%
5Y OCF/share CAGR above 1.5x AGEN's 18.18%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
68.32%
3Y OCF/share CAGR above 1.5x AGEN's 26.37%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-1414.90%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
92.17%
Positive 5Y CAGR while AGEN is negative. John Neff might view this as a strong mid-term relative advantage.
80.18%
3Y net income/share CAGR above 1.5x AGEN's 42.55%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1411.37%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-77.60%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-28.05%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.41%
Asset growth above 1.5x AGEN's 4.91%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
13.37%
BV/share growth above 1.5x AGEN's 0.74%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-15.85%
We’re deleveraging while AGEN stands at 51.63%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
22.47%
R&D dropping or stable vs. AGEN's 1479.65%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-1.59%
We cut SG&A while AGEN invests at 39.29%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.